Detalhe da pesquisa
1.
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(5): 702-715, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33862000
2.
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study.
Gut
; 69(4): 681-690, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31780575
3.
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control.
Oncology
; 90(2): 88-96, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26784946
4.
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
BMC Cancer
; 16: 412, 2016 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27389564
5.
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Lancet Oncol
; 15(3): 305-14, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24556041
6.
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER PRODIGE 23): Health-related quality of life longitudinal analysis.
Eur J Cancer
; 186: 151-165, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068407
7.
Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial.
Radiother Oncol
; 186: 109742, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315583
8.
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.
Dig Liver Dis
; 55(4): 541-548, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36115817
9.
Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 12(11): 1032-44, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21903473
10.
Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.
BMC Cancer
; 16(1): 518, 2016 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-27457763
11.
Renal function in patients receiving streptozocin for locally advanced or metastatic digestive neuroendocrine tumours: results of the Streptotox-FFCD 0906 study.
Clin Res Hepatol Gastroenterol
; 45(5): 101572, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751987
12.
MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.
Cancers (Basel)
; 13(2)2021 Jan 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33430396
13.
Evaluation of Nurses' and Patients' Overall Satisfaction with New and Previous Formulations of Octreotide Long-acting Release (Sandostatin LAR®): A French Observational Study.
Adv Ther
; 37(9): 3901-3915, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32683667
14.
Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma.
Cancers (Basel)
; 12(6)2020 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-32486421
15.
Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCD 2000-05 trial.
Expert Rev Pharmacoecon Outcomes Res
; 19(5): 601-608, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30739558
16.
Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials.
Eur J Cancer
; 98: 1-9, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29807237
17.
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
J Clin Oncol
; 23(36): 9250-6, 2005 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16361622
18.
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
Gastroenterol Clin Biol
; 30(3): 357-63, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16633299
19.
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
J Clin Oncol
; 22(21): 4319-28, 2004 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15514373
20.
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Gastroenterol Clin Biol
; 29(11): 1113-24, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16505756